Sosei announces progression of SD118 for the treatment of neuropathic pain towards Phase 1 studies

26-Feb-2007

Sosei Group Corporation announced that its collaborative project SD118, which is under development for the treatment of neuropathic pain, has successfully completed regulatory pre-clinical studies and will now be progressed into Phase 1 clinical trials.

SD118 is being jointly developed with NeuroDiscovery Ltd and its wholly owned subsidiary NeuroSolutions Ltd under a Collaboration Agreement concluded in June 2006. SD118 was previously under investigation in Japan for a different indication and now, following re-profiling, has demonstrated its potential as a new oral neuropathic pain therapy.

Sosei will shortly make a Clinical Trial Application in the UK to facilitate the Phase 1 trials commencement.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...